M&A Activity • Jan 22, 2021
M&A Activity
Open in ViewerOpens in native device viewer
PRESS RELEASE
Trento, 22 January 2021
GPI S.p.A. (GPI:IM), a leading company in IT Solutions and Healthcare and Social Services, listed on the MTA market of Borsa Italiana, announces that today it has completed the acquisition of the residual 40% of shares of its subsidiary Hemasoft Software S.L., leader of the Spanish group of the same name, for 5.7 million Euros. GPI is now the sole owner of the Hemasoft Group, as previously agreed upon in the contract signed on September 15, 2017 and made public on that same date. Hemasoft Software S.L. holds in turn the 100% of shares of Hemasoft America Corporation (Miami, USA).
Hemasoft is an international group with branches in Spain and in the USA, boasts an excellent network of customers and partners in over 50 countries around the world. Of note, among the latest contracts awarded, the supplies for the Donation and Transfusion Network of the Pais Vasco (Osakidetza) in Spain, the Kuwait Central Blood Bank, Al Jabiriyah, the Austral Blood Center and Transfusion Network in Chile, and the Colombian Hematology Foundation. Moreover, among the main customers of Hemasoft there are: the Spanish transfusion services (Galicia, Asturias, Cantabria, Castilla Leon, Navarra, Aragon, Castilla la Mancha and Pais Vasco) and the Honduran, Ecuadorian, Lebanese and Australian Red Cross. Noteworthy is the recent update of the FDA certification that allows the Hemasoft's software solution, called eDelphyn, to be marketed in the US market.
The Hemasoft Group reported consolidated Revenue of 4.2 million Euros and an EBITDA margin of 45% in 2019.
The acquisition of the entirety of the Hemasoft Group is a key element in the development of GPI4Blood, the Business Unit of the GPI Group committed to the software solutions for Blood Management that enable the efficient and safe management of Blood Centers, Hospital Blood Banks, Organ, Tissue and Stem Cell Banks and testing laboratories. This Business Unit includes the activities of the Hemasoft Group, the assets of the American company Haemonetics acquired by GPI USA, the Medinfo Group, Guyot Walser Informatique as well as GPI's activities in the sector, which holds approximately 50% of the Italian blood transfusion market.
GPI is the partner of reference for software, technologies and services dedicated to healthcare, social care and public administration. Founded over 30 years ago in Trento, Italy, GPI has grown thanks to significant investments in M&A (in Italy and abroad) and R&D, carried out in partnership with the main Italian universities and research organizations with the aim of transferring scientific, technological, functional and process know-how applied to the e-health, e-welfare, well-being sectors. Thanks also to the solutions and the specialized expertise passed on from companies who became part of the GPI ecosystem, the Group has managed to translate emerging needs from healthcare into cutting-edge technological solutions and new service models capable of optimizing prevention processes, diagnosis and treatment, improving people's quality of life.
The products combine specialist expertise in IT and consultancy and design skills, which allow GPI to operate in different business areas: Software, Care, Automation, ICT and Pay.
In 2019 the Company delivered consolidated revenues of 241 million Euros, over 5,300 employees and more than 2,200 customers spread over 60 countries.
In 2016 GPI was listed on Borsa Italiana AIM market and graduated to MTA market in 2018. ISIN common shares: IT0005221517 - ISIN "Warrant GPI SpA": IT0005221475
Press release at www.Gpi.it and
GPI | Fabrizio Redavid, Lorenzo Giollo | [email protected] | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento
GPI | Daniela Filbier, Enrico Orfano| [email protected] | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento
Banca Akros | Bruno Mestice | [email protected] | T. +3902434441 | Viale Eginardo, 29 – 20149 Milano
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.